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hemists have created impressive collections 
of small molecules in recent years. The 
Molecular Libraries Program, for example, 
contains  information  on  more  than  300,000   
different molecules, and PubChem lists chemical 
structures and the results of experimental investi-
gations for some 5.5 million unique molecules. 
This immense amount of chemical information, 
combined with the availability of fully sequenced 
genomes for a growing number of hosts and 
pathogens, could in theory accelerate efforts to 
identify new drugs for the treatment of a variety 
of diseases. In practice, however, sampling the 
complete chemical space to discover molecules 
with therapeutic potential is inefficient. Instead, 
using a handful of carefully selected compounds 
that identify a limited set of targets may be a 
more  fruitful  means  of  uncovering  candidate 
drugs.
African  sleeping  sickness,  or  trypanosomi-
asis, is a neglected tropical disease caused by 
the  protozoan  parasite  Trypanosoma  brucei 
(Kennedy, 2013). Untreated, the disease is often 
fatal, and the latest treatment, eflornithine, while 
still effective, is over 50 years old. The genomes of 
several strains of T. brucei have been sequenced, 
and together they contain genes that code for 
about 9000 proteins, including about 1700 that 
are specific to T. brucei (Berriman et al., 2005). 
Now, in eLife, Jack Taunton and colleagues at the 
University of California, San Francisco—including 
Mari Nishino, Jonathan Choy and Nathan Gushwa 
as joint first authors—report a chemoproteomics 
approach to focus their search for drug targets in a 
way that creates a clear path to new trypanosomi-
asis therapies (Nishino et al., 2013).
Chemoproteomics is a relatively recent entry 
in the -omics lexicon, and involves using chemical 
tools, often small molecules, to identify a group 
of functionally related proteins (Moellering and 
Cravatt, 2012). The UCSF team began by selecting 
protein kinases as their intended targets because 
inhibiting these enzymes in other systems is often 
lethal. As well as playing essential roles in the 
cell, kinases are druggable: that is, small mole-
cules have been developed that can selectively 
inhibit these proteins in a variety of screening 
assays. More importantly, some of these small-
molecule  inhibitors  have  become  effective 
drugs:  Gleevec  (imatinib),  the  tyrosine-kinase 
inhibitor  used  to  treat  chronic  myelogenous 
leukemia and other cancers, is probably the best 
known.
The T. brucei genome encodes 182 protein 
kinases, most with poorly understood functions. 
The UCSF team focused on a subset of 21 T. brucei 
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kinases that had a cysteine residue near their 
active sites (Schirmer et al., 2006). Most of these 
‘CDXG kinases’, named after the motif found at 
their active sites, were expected to react with and 
be inhibited by a proven CDXG inhibitor called 
hypothemycin (Nair and Carey, 1980; Agatsuma 
et al., 1993) (Figure 1). Hypothemycin is a com-
pound produced by several fungal species, and it 
can inhibit some CDXG kinases by reacting with a 
cysteine residue at the active site.
The UCSF team first established that hypothe-
mycin killed T. brucei at therapeutically significant 
(sub-µM) levels in vitro, and then found that it 
reduced the parasite load in vivo in a mouse 
model. However, higher levels of hypothemycin 
resulted in toxicity, which means that the dose 
cannot be increased to a level that would com-
pletely eliminate the parasites. CDXG kinases 
are  conserved  in  mammals,  and  these  results 
highlight the liability of kinase inhibitors that lack 
sufficient host/parasite selectivity. Significantly, 
however, while hypothemycin could kill parasites 
in a mammalian host, it was not established that it 
did so by inhibiting CDXG kinases, or if it did, which 
of the 21 such kinases in T. brucei was affected.
The team then employed an impressive array 
of experimental techniques in an effort to identify 
the kinase that was targeted by hypothemycin. 
They also chemically modified hypothemycin to 
make it easy to detect (without altering its bio-
logical activity). In a follow-up assay, this modified 
hypothemycin labeled 11 proteins, all of which 
were CDXG kinases. More quantitative studies 
reduced these 11 potential targets to two, and 
still further studies fingered a single kinase called 
TbCLK1. An RNAi knockdown of TbCLK1 inde-
pendently showed that it was essential in T. brucei.
What  did  the  chemoproteomics  approach 
accomplish in this study? First, it allowed Taunton 
and colleagues to define the activity of a single 
molecule, hypothemycin, in a whole-organism 
assay that, by its very nature, includes all targets. 
Secondly, since hypothemycin had a known mech-
anism of action—covalently inhibiting a small class 
of  kinases  by  reaction  with  a  critical  cysteine 
residue—the  initial  search  for  the  target  was 
greatly simplified. By narrowing down the original 
set of plausible suspects to TbCLK1, the UCSF 
team illustrated the power of systematically apply-
ing several new technologies.
An important point, which Taunton and co-
workers diplomatically mention only in passing, is 
that more inclusive assays to identify druggable 
T. brucei kinases failed to capture TbCLK1 as a 
potential  therapeutic  target.  This  discrepancy 
likely results from the experimental differences 
between probing cell lysates with small mole-
cules  and  probing  whole  organisms.  So  the 
hypothemycin-based chemoproteomics approach, 
with its early attention to mechanism and target 
structure, yielded a significant dividend.
Hypothemycin’s disadvantages as a therapy, 
including the fact that it inhibits several human 
kinases (Schirmer et al., 2006), will prevent it 
from being developed as a new drug to treat 
human African trypanosomiasis. But there is room 
for optimism, as large numbers of kinase inhibitors 
already exist and may be repurposed to inhibit 
TbCLK1 or related factors in parasites that cause 
other neglected tropical diseases. Importantly, 
the amino-acid sequences of human and T. brucei 
CLK1s are dissimilar, so TbCLK1 holds promise as 
a drug target. Further studies should enable the 
development of inhibitors that preferentially bind 
the  parasite  kinase  and  cure  trypanosomiasis 
without being toxic to humans.
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Figure 1. The kinase inhibitor hypothemycin has been 
used to identify a druggable kinase to combat African 
sleeping sickness. Here a ball-and-stick molecular 
model of hypothemycin is overlaid on an image of 
Hypomyces subiculosus (orange), the fungus from 
which it was originally isolated over thirty years ago. PHOTOGRAPH: MASANORI KUTSUNAChemical biology | Closing in on a new treatment for sleeping sickness
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